Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus

Affiliations

¹ Duke Clinical Research Institute, Durham, NC (C.B.G.).
² The Stanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine, Palo Alto, CA (K.W.M.).

Editorial

Christopher B Granger et al. Circulation. 2020.

. 2020 Apr 14;141(15):1235-1237.

doi: 10.1161/CIRCULATIONAHA.120.045864. Epub 2020 Apr 13.

¹ Duke Clinical Research Institute, Durham, NC (C.B.G.).
² The Stanford Center for Clinical Research, Department of Medicine, Stanford School of Medicine, Palo Alto, CA (K.W.M.).

No abstract available

Keywords: Editorials; atrial fibrillation; diabetes mellitus, type 2; heart failure; sodium-glucose cotransporter 2 inhibitors.

Comment on

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Zelniker TA, et al. Circulation. 2020 Apr 14;141(15):1227-1234. doi: 10.1161/CIRCULATIONAHA.119.044183. Epub 2020 Jan 27. Circulation. 2020. PMID: 31983236